Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income

Reuters

2小时前

Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income

Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.
In China, 国家药监局 accepted the biological products license application for 贝伐单抗玻璃体腔内注射液 (TAB014), supporting a potential first-mover position in a wAMD-focused bevacizumab filing.
For 硫酸阿托品滴眼液 (NVK002), 国家药监局 accepted the simplified new drug application for the 0.01% dose and accepted the new drug application for the 0.02% dose, keeping both formulations under review as potential growth drivers.
In the US, FDA approved the new drug investigational application for 环孢素眼用凝胶 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.
Commercial readiness was supported by RMB 959 million in cash and cash equivalents, while loss narrowed to RMB 209 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067098), on March 25, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/news/2622078184"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622078184\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622078184?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-25 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622078184","market":"fut","top_or_hot":-1,"title":"Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.\n        </li>\n<li>\n          In China, 国家药监局 accepted the biological products license application for 贝伐单抗玻璃体腔内注射液 (TAB014), supporting a potential first-mover position in a wAMD-focused bevacizumab filing.\n        </li>\n<li>\n          For 硫酸阿托品滴眼液 (NVK002), 国家药监局 accepted the simplified new drug application for the 0.01% dose and accepted the new drug application for the 0.02% dose, keeping both formulations under review as potential growth drivers.\n        </li>\n<li>\n          In the US, FDA approved the new drug investigational application for 环孢素眼用凝胶 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.\n        </li>\n<li>\n          Commercial readiness was supported by RMB 959 million in cash and cash equivalents, while loss narrowed to RMB 209 million.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067098), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.\n        </li>\n<li>\n          In China, 国家药监局 accepted the biological products license application for 贝伐单抗玻璃体腔内注射液 (TAB014), supporting a potential first-mover position in a wAMD-focused bevacizumab filing.\n        </li>\n<li>\n          For 硫酸阿托品滴眼液 (NVK002), 国家药监局 accepted the simplified new drug application for the 0.01% dose and accepted the new drug application for the 0.02% dose, keeping both formulations under review as potential growth drivers.\n        </li>\n<li>\n          In the US, FDA approved the new drug investigational application for 环孢素眼用凝胶 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.\n        </li>\n<li>\n          Commercial readiness was supported by RMB 959 million in cash and cash equivalents, while loss narrowed to RMB 209 million.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067098), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL94t3zx:1","article_id":"2622078184","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622078184","pubTimestamp":1774439016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.In China, 国家药监局 accepted the biological products license application for 贝伐单抗玻璃体腔内注射液 , supporting a potential first-mover position in a wAMD-focused bevacizumab filing.In the US, FDA approved the new drug investigational application for 环孢素眼用凝胶 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1587":"次新股","BK1574":"生物医药B类股","BK1583":"高瓴概念","06622":"兆科眼科-B","BK1191":"制药"},"translate_title":"Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":0.9},"content_text":"Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income\n    \n\n\n          Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.\n        \n\n          In China, 国家药监局 accepted the biological products license application for 贝伐单抗玻璃体腔内注射液 (TAB014), supporting a potential first-mover position in a wAMD-focused bevacizumab filing.\n        \n\n          For 硫酸阿托品滴眼液 (NVK002), 国家药监局 accepted the simplified new drug application for the 0.01% dose and accepted the new drug application for the 0.02% dose, keeping both formulations under review as potential growth drivers.\n        \n\n          In the US, FDA approved the new drug investigational application for 环孢素眼用凝胶 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.\n        \n\n          Commercial readiness was supported by RMB 959 million in cash and cash equivalents, while loss narrowed to RMB 209 million.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067098), on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}